Study of Blood Immune Cells in Cancer Patients Compared to Controls
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01312701|
Recruitment Status : Unknown
Verified March 2011 by Hadassah Medical Organization.
Recruitment status was: Recruiting
First Posted : March 11, 2011
Last Update Posted : March 11, 2011
Tumors have a systemic immune modifying effect. They affect the immune system similarly to states of chronic inflammation and these effects can:
- be monitored through analysis of nk t and myeloid cells mainly through studies of the zeta chain but also through other means
- may be decreased following effective anticancer therapy - may even be used to study the effectiveness of anticancer therapy
- are important to monitor if the investigators plan on formulation of systemic immune therapy Thus immumonitoring of systemic blood cells may turn out to be an important prognostic and predictive factor in many cancer types
|Condition or disease|
CD247 Known also as the zeta chain is important for relaying T-cell induced signal transduction.
Interestingly studies by Baniash and others have demonstrated that this chain is down regulated in states of chronic inflammation and cancer in peripheral blood T cells and also in NK cells However there has not been a prospective study of this marker in cancer and control patients such a study will reveal not only the levels of CD247 in immune cells of cancer patients compared to controls but may reveal the effect of anticancer therapies on CD247 in cancer patients such a study may contribute significantly to our ability to monitor systemic immune system characteristics in cancer patients and help in any further studies of immunomodulation such as vaccination schemes in such patients
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Observational Immunomonitoring Study of NK/T and Myelocites Status in Cancer Patients and Controls|
|Study Start Date :||March 2011|
|Estimated Primary Completion Date :||March 2013|
|Estimated Study Completion Date :||December 2013|
as described patietns with solid cancer about to be treated with anticancer therapies
normal populations who domated blood for further use
- changes in immune markers mainly cd247-zeta chain - levels in cancer patients undergoing therapy [ Time Frame: 4-2013 24 month ]Hopefully by this time the investigators will be able to see if there are lower zeta chain intracellular expression levels in cancer patients and whether response to therapy enhances recovery of zeta chain
- levels of zeta chain -cd247 in cancer patients [ Time Frame: till begining of 2013 ( putative) ]intracellular levels of cd247 compared to other intracellular proteins and other markers of immune response will be monitored in patients with cancer and a control group in cancer patients the investigators will conduct several tests to analyze effects of therapy
Biospecimen Retention: Samples Without DNA
The investigators will collect peripheral blood for facts analysis of intracellular levels of proteins.
Some of these cells may be frozen for longer periods of time for comparison with other new samples.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01312701
|Contact: Hovav Nechushtan, MD PHD||972 508946057||HOVAVNECH@hadassah.org.il|
|Contact: Moshe sade, BSC||97226776750 ext firstname.lastname@example.org]|
|Oncology day care Oncology Dept Sharett Inst Hadassah Ein Kerem||Recruiting|
|Jerusalem, Israel, 91120|
|Contact: Tamar Hamburger, BA 97226777745 Tamarh@hadassah.org.il|
|Principal Investigator: hovav nechushtan, md phd|
|Principal Investigator:||Hovav Nechushtan, MD PhD||Oncology Dept Hadassah Hebrew University Medical Center|